Putting Lecanemab into Practice: A Clinician’s Perspective on the New Alzheimer’s Treatment
Source: https://www.podbean.com/eau/pb-x65mi-... On July 6, 2023, the U.S. Food and Drug Administration (FDA) granted full approval for the Alzheimer’s disease drug Leqembi (lecanemab-irmb), the first medicine shown to delay the course of the disease. Having gone through a rigorous approval process, the medication exemplifies a critical advancement in the ongoing battle to treat Alzheimer’s disease. Having already prescribed the treatment to real-life patients, Dr. Robert Przybelski joins the podcast to discuss his experience prescribing and administering lecanemab, what clinicians and patients should discuss when considering these treatments, and what is needed to integrate these treatments into the healthcare system. Guest: Robert Przybelski, MD, MS, director, Geriatric Memory Clinics, UW Health, professor, Division of Geriatrics and Gerontology, University of Wisconsin School of Medicine and Public Health Show Notes Read more about Lecanemab’s Appropriate Use Guidelines on our website: https://www.adrc.wisc.edu/sites/defau... Read the FDA’s press release, “FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval": https://www.fda.gov/news-events/press... Listen to previous Dementia Matters episodes on lecanemab, “Introducing Lecanemab, The Latest Alzheimer’s Disease Drug to Receive FDA Accelerated Approval,” and “A Closer Look at the Lecanemab Clinical Trials,” on our website and all major podcast platforms: https://www.adrc.wisc.edu/dementia-ma..., https://www.adrc.wisc.edu/dementia-ma... Listen to Dr. Przybelski’s previous episode of Dementia Matters, “Vitamin Deficiency And Its Impact On Brain Health,” on our website, Spotify, Apple Podcasts, Podbean, and all major podcast platforms: https://www.adrc.wisc.edu/dementia-ma... Connect with us Find transcripts and more at our website: https://www.adrc.wisc.edu/dementia-ma... Email Dementia Matters: [email protected] Follow us on Facebook and Twitter: / wisconsinadrc , / wisconsinadrc Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter: https://www.adrc.wisc.edu/newsletter

Healing, Opportunity, Progress and Empowerment: Conversations from Haymarket Center's Medical Clinic

Global Trade Outlook: The USMCA and Beyond | Markets Plus

Where Capital Flows Next: Canada’s Evolving Sustainable Finance Market | Sustainability Leaders

Introducing Lecanemab, the Latest Alzheimer’s Disease Drug to Receive FDA Accelerated Approval

Our Evolving Understanding of Mild Cognitive Impairment

The New Alzheimer’s Drug: What is Leqembi?

What do tech pioneers think about the AI revolution? - The Engineers, BBC World Service

Leqembi & Kisunla: New Alzheimer's Treatments Explained | Dr. Armen J. Moughamian

Alzheimer's: The Caregiver's Perspective

I Was An MIT Educated Neurosurgeon Now I'm Unemployed And Alone In The Mountains How Did I Get Here?

Understanding The Stages of Dementia | LiveTalk | Being Patient

The World's Leading Autism Expert - Professor Sir Simon Baron-Cohen

7 Early DEMENTIA Signs That Appear YEARS Before Memory Loss - How to Prevent

What is Dementia?

Promoting Equity through Wellbeing - HSE Talking Health and Wellbeing Podcast –

Posture, Bone Density & Muscle: A Stanford Doctor Destroys Aging Myths Most People Believe

The Professor Who Taught People How To Think (1962)

Billionaire's WARNING: I'm SELLING. The Crash Is Already Here!

Meet the Former CIA Agent Who Wants to Abolish the CIA

